Nanalysis Scientific is showing signs that its operational restructuring is beginning to translate into better financial performance. The portable NMR spectroscopy company reported C$9.7 million in second-quarter revenue and C$881,000 in Adjusted EBITDA, reversing an EBITDA loss from a year earlier even as product sales remained under pressure.
For Nanalysis Scientific, the latest quarter was less about rapid top-line growth than proving that operational changes can improve the economics of a specialized scientific-instrumentation business.
The Canadian company reported C$9.72 million in revenue for the three months ended June 30, 2026, up 1.5% from C$9.58 million in the same period last year. More significant was the move in Adjusted EBITDA: Nanalysis generated C$881,000, compared with a C$462,000 loss a year earlier.
The company also narrowed its net loss to C$666,000, from C$2.12 million in the second quarter of 2025.
Nanalysis develops portable nuclear magnetic resonance (NMR) spectrometers and imaging technology for research, industrial and government applications. Its business combines scientific equipment with security services, creating a somewhat unusual revenue mix for an analytical-instrumentation company.
The second-quarter numbers show that the services side is currently doing more of the heavy lifting.
Services are offsetting weaker equipment sales
Nanalysis reported C$5.84 million in services revenue during the quarter, a 3.9% increase from a year earlier. Product sales, by contrast, declined 3.6% to C$2.80 million.
The difference becomes more pronounced over the first half of 2026. Product sales fell 24.5% to C$4.98 million, while services revenue rose 10.4% to C$11.74 million.
A major contributor was the company’s Security Services operation, which saw higher project-related work associated with its airport security maintenance business.
That shift matters because recurring or service-oriented revenue can provide a different economic profile from equipment sales. Instrument purchases tend to be lumpy and dependent on capital budgets, while maintenance and project services can provide a more predictable revenue base.
Nanalysis said its Security Services gross margin increased to 12% in the second quarter, compared with 10% a year earlier. For the first six months, the margin reached 16%, up from 8% in the comparable period.
Management attributed the improvement to logistics changes, better control of overtime and on-call hours, and increased project activity.
Product gross margin also improved during the quarter, reaching 65% versus 61% a year earlier.
The turnaround is primarily operational
The strongest signal in Nanalysis’ results is therefore not revenue growth. It is operating leverage.
The company said lower sales and marketing expenses, reduced general and administrative costs, operational improvements and the filing of eligible investment tax credits contributed to the EBITDA improvement.
For the first six months of 2026, Adjusted EBITDA was C$1.17 million, compared with a C$282,000 loss in the first half of 2025.
That represents a C$1.46 million improvement despite essentially flat consolidated revenue.
Nanalysis also said it remained compliant with the financial covenants attached to its ATB term loan and line of credit as of June 30. The company is continuing efforts to reduce debt and strengthen its balance sheet following a difficult 2025.
For investors and enterprise customers, that distinction is important. A scientific-equipment manufacturer can show attractive technology but still struggle commercially if manufacturing costs, sales channels and service operations are not tightly managed. Nanalysis’ latest results suggest management is attempting to fix those operational constraints before pursuing faster growth.
Portable NMR addresses a long-standing instrumentation problem
NMR spectroscopy is an established analytical technique used to characterize molecules and materials, with applications spanning pharmaceuticals, biotechnology, chemicals, food science and academic research.
The traditional equipment market, however, has generally been associated with large, expensive systems. Grand View Research estimates the global NMR spectroscopy market will reach approximately US$840.5 million in 2026, growing to about US$1.03 billion by 2030 at a 5.1% CAGR. The research firm identifies Nanalysis among the established companies operating in the market alongside Bruker, JEOL, Magritek and Oxford Instruments.
That creates an opening for lower-field and portable NMR systems.
Nanalysis’ value proposition is essentially to make NMR analysis more accessible in environments where a conventional high-field laboratory system may be impractical. Portable instrumentation can be relevant to industrial quality control, chemical analysis, process monitoring, teaching and field applications.
The market is also benefiting from broader investment in pharmaceutical and biomedical research. Grand View Research estimates the high- and ultra-high-field NMR segment alone could grow from US$632.9 million in 2026 to US$1.03 billion by 2035.
Nanalysis does not compete with every high-field system on raw analytical performance. Its opportunity is more focused: applications where portability, accessibility, cost and deployment flexibility matter.
Distributor strategy could determine the next growth phase
The company’s international distribution network is another important piece of the story.
Nanalysis said distributor-led sales in 2026 are currently on track to at least double from the prior year. That is significant because specialized scientific instruments often require technical sales support and regional expertise.
A stronger distributor network can give a smaller instrumentation company broader geographic reach without requiring the same level of direct commercial infrastructure in every market.
The challenge is converting that channel expansion into sustained product revenue. The first-half decline in product sales shows that the company’s commercial recovery is not complete.
Management has also said it is prioritizing research and development toward higher-value opportunities and strengthening its go-to-market organization.
What enterprise buyers should watch
For laboratories, pharmaceutical companies, chemical manufacturers and government agencies evaluating analytical instrumentation, the relevant question is increasingly whether NMR can move beyond centralized research laboratories.
Portable systems could make molecular analysis more accessible in production environments and locations where transporting samples to a central laboratory is inefficient.
But buyers will still evaluate sensitivity, resolution, workflow integration, software capabilities, service coverage and total cost of ownership against conventional high-field NMR systems and alternative analytical techniques such as mass spectrometry, infrared spectroscopy and chromatography.
That competitive context puts pressure on vendors to demonstrate not simply that portable NMR works, but that it solves a specific operational problem better than an existing laboratory workflow.
Nanalysis’ latest quarter suggests the company is simultaneously trying to improve that product proposition and repair the commercial engine around it.
The financial results do not yet show a major growth breakout. They do show something arguably more important at this stage: revenue has stabilized while profitability metrics have improved sharply.
Whether that becomes durable growth will depend on product demand, international distribution and continued improvement in the company’s services business through the remainder of 2026.
Market Landscape
NMR spectroscopy remains a specialized but important component of scientific instrumentation, particularly across pharmaceutical research, biotechnology, chemical analysis and academia.
The broader NMR spectroscopy market is projected to grow at approximately 5.1% annually through 2030, according to Grand View Research. The research firm identifies increasing biomedical research investment, pharmaceutical applications and the expansion of NMR into non-healthcare industries among the market’s growth drivers.
The competitive landscape includes large scientific-instrument companies such as Bruker, JEOL and Oxford Instruments, alongside specialized vendors including Nanalysis and Magritek. The market is divided between high-field laboratory systems and lower-field, compact or portable instruments.
That creates two different competitive propositions. High-field NMR emphasizes analytical capability and sensitivity, while portable NMR emphasizes accessibility, deployment flexibility and potentially lower infrastructure requirements.
For Nanalysis, the opportunity is therefore not necessarily to displace the largest laboratory systems. It is to expand the number of environments in which NMR becomes economically and operationally practical.
Top Insights
- Nanalysis generated C$9.72 million in Q2 revenue, while Adjusted EBITDA reached C$881,000, marking a substantial profitability improvement despite limited top-line growth.
- Services revenue is becoming increasingly important, rising 3.9% year over year as Security Services benefited from airport maintenance projects and operational efficiency improvements.
- First-half product sales declined 24.5%, highlighting the commercial challenge Nanalysis faces even as distributor-led sales and international channel development accelerate.
- The NMR spectroscopy market continues expanding, with Grand View Research forecasting approximately 5.1% annual growth through 2030 across pharmaceutical, research and industrial applications.
- Portable NMR offers a different competitive proposition, targeting organizations that need molecular analysis closer to production, field or decentralized research environments.
Get in touch with our fintech expert
